Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 5-6/2017

27.11.2017 | ORIGINAL ARTICLE

A New Class III Antiarrhythmic Drug Niferidil Prolongs Action Potentials in Guinea Pig Atrial Myocardium via Inhibition of Rapid Delayed Rectifier

verfasst von: Denis V. Abramochkin, Vladislav S. Kuzmin, Leonid V. Rosenshtraukh

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 5-6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A new class III antiarrhythmic drug niferidil (RG-2) has been introduced as a highly effective therapy for cases of persistent atrial fibrillation, but ionic mechanisms of its action are poorly understood. In the present study, the effects of niferidil on action potential (AP) waveform and potassium currents responsible for AP repolarization were investigated in guinea pig atrial myocardium.

Methods

APs were recorded with sharp glass microelectrodes in multicellular atrial preparations. Whole-cell patch-clamp technique was used to measure K+ currents in isolated myocytes.

Results

In multicellular atrial preparations, 10−8 M niferidil effectively prolonged APs by 15.2 ± 2.8% at 90% repolarization level. However, even the highest tested concentrations, 10−6 M and 10−5 M failed to prolong APs more than 32.5% of control duration. The estimated concentration of niferedil for half-maximal AP prolongation was 1.13 × 10−8 M. Among the potassium currents responsible for AP repolarization phase, I K1 was found to be almost insensitive to niferidil. However, another inward rectifier, I KACh, was effectively suppressed by micromolar concentrations of niferidil with IC50 = 9.2 × 10−6 M. I KATP was much less sensitive to the drug with IC50 = 2.26 × 10−4 M. The slow component of delayed rectifier, I Ks, also demonstrated low sensitivity to niferidil—the highest used concentration, 10−4 M, decreased peak I Ks density to 46.2 ± 5.5% of control. Unlike I Ks, the rapid component of delayed rectifier, I Kr, appeared to be extremely sensitive to niferidil. The IC50 was 1.26 × 10−9 M. I Kr measured in ventricular myocytes was found to be less sensitive to niferidil with IC50 = 3.82 × 10−8 M.

Conclusions

Niferidil prolongs APs in guinea pig atrial myocardium via inhibition of I Kr.
Literatur
1.
Zurück zum Zitat Mittal S, Ayati S, Stein KS, et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation. 2000;101:1282–7.CrossRefPubMed Mittal S, Ayati S, Stein KS, et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation. 2000;101:1282–7.CrossRefPubMed
2.
Zurück zum Zitat Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol. 1997;29:385–90.CrossRefPubMed Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol. 1997;29:385–90.CrossRefPubMed
3.
Zurück zum Zitat Nørgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J. 1999;137:1062–9.CrossRefPubMed Nørgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J. 1999;137:1062–9.CrossRefPubMed
4.
Zurück zum Zitat Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000;102:2385–90.CrossRefPubMed Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000;102:2385–90.CrossRefPubMed
5.
Zurück zum Zitat Bianconi L, Castro A, Dinelli M, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicenter, randomized, double-blind, placebo-controlled study. Eur Heart J. 2000;21:1265–73.CrossRefPubMed Bianconi L, Castro A, Dinelli M, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicenter, randomized, double-blind, placebo-controlled study. Eur Heart J. 2000;21:1265–73.CrossRefPubMed
6.
Zurück zum Zitat Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518–25.CrossRefPubMed Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518–25.CrossRefPubMed
7.
Zurück zum Zitat Camm AJ, Lip GYH, Caterina R, et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–47.CrossRefPubMed Camm AJ, Lip GYH, Caterina R, et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–47.CrossRefPubMed
8.
Zurück zum Zitat Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996;28:130–6.CrossRefPubMed Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996;28:130–6.CrossRefPubMed
9.
Zurück zum Zitat Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, Vanderlugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 1996;94:1613–21.CrossRefPubMed Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, Vanderlugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 1996;94:1613–21.CrossRefPubMed
10.
Zurück zum Zitat Maykov EB, Yuricheva YA, Mironov NY, et al. Efficacy of a new class III drug niferidil in cardioversion of persistent atrial fibrillation and flutter. J Cardiovasc Pharmacol. 2014;64:247–55.CrossRefPubMed Maykov EB, Yuricheva YA, Mironov NY, et al. Efficacy of a new class III drug niferidil in cardioversion of persistent atrial fibrillation and flutter. J Cardiovasc Pharmacol. 2014;64:247–55.CrossRefPubMed
11.
Zurück zum Zitat Abramochkin DV, Kuzmin VS, Rosenshtraukh LV. Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms. Naunyn Schmiedeberg's Arch Pharmacol. 2015;388:1105–12.CrossRef Abramochkin DV, Kuzmin VS, Rosenshtraukh LV. Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms. Naunyn Schmiedeberg's Arch Pharmacol. 2015;388:1105–12.CrossRef
12.
Zurück zum Zitat Liu GX, Zhou J, Koren G. Single-channel properties of IK,slow1 and IK,slow2 in mouse ventricular myocytes. Pflugers Arch. 2008;456:541–7.CrossRefPubMed Liu GX, Zhou J, Koren G. Single-channel properties of IK,slow1 and IK,slow2 in mouse ventricular myocytes. Pflugers Arch. 2008;456:541–7.CrossRefPubMed
13.
Zurück zum Zitat Brouillette J, Clark RB, Giles WR, Fiset C. Functional properties of K+ currents in adult mouse ventricular myocytes. J Physiol. 2004;559:777–98.CrossRefPubMedPubMedCentral Brouillette J, Clark RB, Giles WR, Fiset C. Functional properties of K+ currents in adult mouse ventricular myocytes. J Physiol. 2004;559:777–98.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 1990;96:195–215.CrossRefPubMed Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 1990;96:195–215.CrossRefPubMed
15.
Zurück zum Zitat Isenberg G, Klockner U. Calcium tolerant ventricular myocytes prepared by preincubation in a ‘KB-medium. Pflugers Arch. 1982;395:6–18.CrossRefPubMed Isenberg G, Klockner U. Calcium tolerant ventricular myocytes prepared by preincubation in a ‘KB-medium. Pflugers Arch. 1982;395:6–18.CrossRefPubMed
16.
Zurück zum Zitat Bosch RF, Gaspo R, Busch AE, Lang HJ, Li G, Nattel S. Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc Res. 1998;38:441–50.CrossRefPubMed Bosch RF, Gaspo R, Busch AE, Lang HJ, Li G, Nattel S. Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc Res. 1998;38:441–50.CrossRefPubMed
17.
Zurück zum Zitat Eto K, Hashimoto K, Nakaya H. Preferential inhibition of IKr by MCI-154, a putative cardiotonic Ca2+ sensitizer, in guinea pig atrial cells. Cardiovasc Res. 1998;38:685–94.CrossRefPubMed Eto K, Hashimoto K, Nakaya H. Preferential inhibition of IKr by MCI-154, a putative cardiotonic Ca2+ sensitizer, in guinea pig atrial cells. Cardiovasc Res. 1998;38:685–94.CrossRefPubMed
18.
Zurück zum Zitat Fedorov VV, Sharifov OF, Beloshapko GG, Yushmanova AV, Rosenshtraukh LV. Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation. J Cardiovasc Pharmacol. 2000;36:77–89.CrossRefPubMed Fedorov VV, Sharifov OF, Beloshapko GG, Yushmanova AV, Rosenshtraukh LV. Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation. J Cardiovasc Pharmacol. 2000;36:77–89.CrossRefPubMed
19.
Zurück zum Zitat Nattel S, Yue L, Wang Z. Cardiac ultrarapid delayed rectifiers: a novel potassium current family of functional similarity and molecular diversity. Cell Physiol Biochem. 1999;9:217–26.CrossRefPubMed Nattel S, Yue L, Wang Z. Cardiac ultrarapid delayed rectifiers: a novel potassium current family of functional similarity and molecular diversity. Cell Physiol Biochem. 1999;9:217–26.CrossRefPubMed
20.
Zurück zum Zitat Li GR, Feng J, Yue L, Carrier M, Nattel S. Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res. 1996;78:689–96.CrossRefPubMed Li GR, Feng J, Yue L, Carrier M, Nattel S. Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res. 1996;78:689–96.CrossRefPubMed
21.
Zurück zum Zitat Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999;51:651–90.PubMed Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999;51:651–90.PubMed
22.
Zurück zum Zitat Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res. 1993;72:75–83.CrossRefPubMed Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res. 1993;72:75–83.CrossRefPubMed
23.
Zurück zum Zitat Larsen AP, Bentzen BH, Grunnet M. Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels. Br J Pharmacol. 2010;161:614–28.CrossRefPubMedPubMedCentral Larsen AP, Bentzen BH, Grunnet M. Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels. Br J Pharmacol. 2010;161:614–28.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Bebarova M, Matejovic P, Pasek M, Horakova Z, Hosek J, Simurdova M, et al. Effect of ethanol at clinically relevant concentrations on atrial inward rectifier potassium current sensitive to acetylcholine. Naunyn Schmiedeberg's Arch Pharmacol. 2016;389:1049–58.CrossRef Bebarova M, Matejovic P, Pasek M, Horakova Z, Hosek J, Simurdova M, et al. Effect of ethanol at clinically relevant concentrations on atrial inward rectifier potassium current sensitive to acetylcholine. Naunyn Schmiedeberg's Arch Pharmacol. 2016;389:1049–58.CrossRef
25.
Zurück zum Zitat Sossalla S, Kallmeyer B, Wagner S, Mazur M, Maurer U, Toischer K, et al. Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 2010;55:2330–42.CrossRefPubMed Sossalla S, Kallmeyer B, Wagner S, Mazur M, Maurer U, Toischer K, et al. Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 2010;55:2330–42.CrossRefPubMed
26.
Zurück zum Zitat Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T, et al. The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation. 2005;112:3697–706.CrossRefPubMed Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T, et al. The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation. 2005;112:3697–706.CrossRefPubMed
Metadaten
Titel
A New Class III Antiarrhythmic Drug Niferidil Prolongs Action Potentials in Guinea Pig Atrial Myocardium via Inhibition of Rapid Delayed Rectifier
verfasst von
Denis V. Abramochkin
Vladislav S. Kuzmin
Leonid V. Rosenshtraukh
Publikationsdatum
27.11.2017
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 5-6/2017
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-017-6762-x

Weitere Artikel der Ausgabe 5-6/2017

Cardiovascular Drugs and Therapy 5-6/2017 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.